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Cancers of unknown primary (CUPs) comprise a heterogeneous group of rare metastatic
tumors whose primary site cannot be identified after extensive clinical–pathological
investigations. CUP patients are generally treated with empirical chemotherapy and have
dismal prognosis. As recently reported, CUP genome presents potentially druggable
alterations for which targeted therapies could be proposed. The paucity of tumor tissue,
as well as the difficult DNA testing and the lack of dedicated panels for target gene
sequencing are further relevant limitations. Here, we propose that circulating tumor
cells (CTCs) and circulating tumor DNA (ctDNA) could be used to identify actionable
mutations in CUP patients. Blood was longitudinally collected from two CUP patients.
CTCs were isolated with CELLSEARCH R© and DEPArrayTM NxT and Parsortix systems,
immunophenotypically characterized and used for single-cell genomic characterization
with Ampli1TM kits. Circulating cell-free DNA (ccfDNA), purified from plasma at different
time points, was tested for tumor mutations with a CUP-dedicated, 92-gene custom
panel using SureSelect Target Enrichment technology. In parallel, FFPE tumor tissue
was analyzed with three different assays: FoundationOne CDx assay, DEPArray LibPrep
and OncoSeek Panel, and the SureSelect custom panel. These approaches identified
the same mutations, when the gene was covered by the panel, with the exception of an
insertion in APC gene. which was detected by OncoSeek and SureSelect panels but not
FoundationOne. FGFR2 and CCNE1 gene amplifications were detected in single CTCs,
tumor tissue, and ccfDNAs in one patient. A somatic variant in ARID1A gene (p.R1276∗)
was detected in the tumor tissue and ccfDNAs. The alterations were validated by Droplet
Digital PCR in all ccfDNA samples collected during tumor evolution. CTCs from a second
patient presented a pattern of recurrent amplifications in ASPM and SEPT9 genes and
loss of FANCC. The 92-gene custom panel identified 16 non-synonymous somatic
alterations in ccfDNA, including a deletion (I1485Rfs∗19) and a somatic mutation (p.
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A1487V) in ARID1A gene and a point mutation in FGFR2 gene (p.G384R). Our results
support the feasibility of non-invasive liquid biopsy testing in CUP cases, either using
ctDNA or CTCs, to identify CUP genetic alterations with broad NGS panels covering the
most frequently mutated genes.
Keywords: CTC, cell-free tumor DNA, cancer of unknown primary, liquid biopsy, precision oncology
INTRODUCTION
Malignant solid tumors that are not fully eradicated at an early
stage are doomed to spread to nearby lymph nodes and organs
and eventually give origin to distant metastases. A diagnosis of
metastatic cancer considerably reduces the chances to eliminate
the tumor and cure the patient. The metastatic process is made
possible by the progressive acquirement of genetic alterations
in tumor cells, which eventually become anchorage independent
and self-sufficient for cell growth. Disseminated tumor cells,
including circulating tumor cells (CTCs) and CTC clusters, are
highly metastatic (Aceto et al., 2014), and their number in the
blood correlates with patient prognosis in several cancer types
(Riethdorf et al., 2007; Joosse et al., 2015; Sparano et al., 2018).
The epitome of advanced cancers could be considered a
particularly aggressive metastatic disease known as cancer of
unknown primary (CUP, also occult primary cancer). CUP
is a rare syndrome of metastatic cancers whose primary site
cannot be identified after detailed physical examinations, blood
analyses, imaging, and immunohistochemical (IHC) testing
(Fizazi et al., 2015). CUPs make up 3–5% of newly diagnosed
cancers worldwide and represent an important clinical problem
(Varadhachary and Raber, 2014; Laprovitera et al., 2021),
specifically when considering that current therapeutic protocols
are primary site oriented. As a final result, CUP patients
receive empirical cytotoxic chemotherapy regimens and have
poor prognosis [average overall survival (OS) 4–9 months, about
20% survive more than 1 year]. It has been reported that
CUPs present actionable genetic alterations (Ross et al., 2015;
Varghese et al., 2017), and these alterations can be identified in
circulating tumor DNA (ctDNA) (Kato et al., 2017). Therefore,
an improvement in CUP treatment and outcome could derive
from clinical trials where patients are treated in accordance to
their specific actionable mutations (Conway et al., 2019), as in
NCT02628379 based on FoundationOne CDx target sequencing
(Roche Foundation Medicine), or basket trials extended to
CUP patients. Moreover, recent studies evidenced how CUP
patients could benefit from treatment with immune checkpoint
inhibitors (Haratani et al., 2019), and clinical trials have been
opened and are currently recruiting (NCT04131621) or positively
concluded (UMIN000030649). In this clinical trial, 56 CUP
patients, of whom 45 previously treated, were treated with anti
PD-1 nivolumab; the objective response rate (ORR) in the overall
population was 21.4%, with a median progression-free survival
(PFS) and OS of 5.1 (95% CI, 2.7–5.6) and 15.9 months (95% CI,
8.4–not reached), respectively (Tanizaki et al., 2020).
CUP genetic testing is currently limited by the scarcity
of tumor biopsy material and reduced biopsy DNA quality;
therefore, a liquid biopsy approach could be of the outmost
interest. Several works demonstrated the utility of ctDNA and
CTC testing to monitor cancer patient prognosis and guide
treatment decisions (Ignatiadis and Dawson, 2014). In addition,
ctDNA variant allele frequency was found to be associated with
a worse prognosis in patients with metastatic disease (Pairawan
et al., 2020); moreover, CTCs became an important clinical
prognostic biomarker (Amintas et al., 2020) with potential
application in in vitro (Zhao et al., 2019) and in vivo disease
modeling (Drapkin et al., 2018) and drug testing (Yu et al., 2014).
Size-based or antigen-based technologies for CTC isolation
and/or enumeration have been developed in the past 10 years,
each one presenting advantages and limitations (Yu et al., 2011).
CUP patients are usually diagnosed with an advanced
metastatic disease; therefore, they are likely to have a high
number of CTCs and CTC clusters in the circulation. Given
the CUP undifferentiated status and variable presentation, it is
yet to demonstrate whether CUP CTCs could be isolated using
tumor antigen selection (Komine et al., 2014). In this study,
we explored liquid biopsy, specifically ctDNA- and CTC-based
applications, as approaches to detect CUP druggable mutations.
We compared two methods to isolate CTCs, one antigen-based,
size-agnostic (CELLSEARCH, Menarini Silicon Biosystems) and
another antigen-agnostic, size-based (Parsortix, ANGLE plc).
CTCs and ctDNA were detectable in the blood of CUP patients
and analyzed for genomic alterations, which were further
compared with genomic alterations identified in tumor biopsy.
MATERIALS AND METHODS
Sample Collection
Two patients (Pt#71 and Pt#95) with a diagnosis of cancer of
unknown origin (CUP) were recruited at Bologna University
Hospital, Italy. The study was conducted in accordance with
the Declaration of Helsinki, and the protocol was approved
by the Ethics Committee Center Emilia-Romagna Region—
Italy (protocol 130/2016/U/Tess). Patients provided written
informed consent.
Metastatic tissue from lymph node (Pt#71) and ampulla of
Vater (Pt#95) was formalin-fixed and paraffin-embedded (FFPE)
and used for tumor DNA collection. For Pt#71, blood sampling
was performed at three different time points: (A) at diagnosis
(August 2018), (B) during FOLFOX-4 treatment (stable disease,
November 2018), and (C) at disease progression (May 2019). For
Pt#95, blood sampling was performed at diagnosis.
Plasma separation was performed via centrifugation at
1,900 × g for 10 min at 4◦C. A variable number (N = 2–5)
of plasma aliquots (1 ml) for each patient was collected and
stored at –80◦C prior to isolation of circulating cell-free DNA
(ccfDNA). PBMCs were isolated from peripheral blood of Pt#95
using Ficoll-Paque Plus (17-1440-02, GE Healthcare, Chicago, IL,
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United States). Briefly, after plasma depletion, an equal volume of
PBS was added to the remaining blood in EDTA tubes. Following,
4 ml of diluted blood was stratified on 3 ml of Ficoll-Paque Plus
and centrifuged at 400 × g for 30 min at room temperature in a
swinging-bucket rotor. The PBMC ring was carefully removed by
pipetting and the pellet was washed with PBS and centrifuged at
100× g for 5 min. Finally, the pellet was stored at –80◦C prior to
proceeding with DNA extraction.
CTC Isolation With CELLSEARCH and
DEPArray NxT
Pt#71 and Pt#95 blood samples were collected at diagnosis.
CELLSEARCH R© system (Menarini Silicon Biosystems, Castel
Maggiore, Italy) was used to enrich and enumerate CTCs,
followed by single-cell isolation with the DEPArray R© NxT
system (Menarini Silicon Biosystems). Briefly, 7.5 ml of
blood was loaded in CELLSEARCH Autoprep R© for EpCAM-
based immunomagnetic capture of CTCs, followed by
immunofluorescent staining (CK-FITC, PD-L1-PE, CD45-
APC, and DAPI using the CELLSEARCH CXC kit in one patient,
and CK-PE, CD45-APC, and DAPI with the CELLSEARCH
CTC kit in the other patient). After CTC enumeration with the
CellTrack Analyzer II, the sample was loaded into a DEParray
Cartridge and single CTCs and leukocytes were isolated with
the DEPArray NxT system (Menarini Silicon Biosystems) from
each sample. A variable number of CTCs and leukocytes, used
as control, were isolated as single cells and then subjected to
whole-genome amplification employing the Ampli1 WGA Kit
(Menarini Silicon Biosystems).
CTC Isolation With the Parsortix System
For Pt#95, tumor cells were enriched from peripheral blood
also using the Parsortix system (ANGLE plc, Guildford,
United Kingdom). Blood cells were forced to pass through a
6.5-µm separator cassette that can capture CTCs based on their
size and deformability properties. Then, to confirm the CTC
nature of retained cells, we stained CTCs using a combination
of anti-human EpCAM-FITC, anti-human CD45-APC (BD
561864/555485), and DAPI for cell nuclei staining. Images
were acquired using a Leica DMI6000 B inverted fluorescence
microscope (Leica Microsystems, Wetzlar, Germany).
DNA Extraction
DNA was extracted from the tumor area after selection by
an expert pathologist, with the guidance of the hematoxylin–
eosin-stained section. The DNA from different areas of FFPE
unstained slides was extracted using the QIAamp DNA FFPE
Tissue Kit (Cat No: 56404, Qiagen, Hilden, Germany) following
the manufacturer’s guidelines (as described in Cinausero et al.,
2019). Normal DNA was extracted from a non-tumor area in
formalin-fixed paraffin-embedded (FFPE) tissue for Pt#71 and
from PBMC for Pt#95. DNA from PBMCs was extracted using
the QIAamp DNA Micro kit (Cat No: 56304, Qiagen, Hilden,
Germany). Ten slices of Pt#71 FFPE tumor tissue were sent to
Roche Foundation Medicine (Cambridge, MA, United States)
for comprehensive genomic profile analysis with FoundationOne
CDx (F1CDx) assay.
ccfDNA was purified from 1 ml of plasma by Maxwell
RSC instrument (Cat No: AS4500, Promega, Madison, WI,
United States) using the Maxwell RSC ccfDNA Plasma Kit (Cat
No: AS1480, Promega). Genomic and ccfDNA were quantified
using the Qubit 4.0 Fluorometer (Cat No: Q33238, Thermo
Fisher Scientific, Waltham, MA, United States) and the Qubit
dsDNA High Sensitivity Assay Kit (Cat No: Q32854, Thermo
Fisher Scientific).
We assessed yields and quality of FFPE-derived gDNAs using
the NGS FFPE QC Kit (Cat No: G9700B, Agilent Technologies,
Santa Clara, CA, United States) according to the producer’s
protocol (G9700-90000, v. E1, May 2018, Agilent Technologies).
Analysis of Tumor Genetic Alterations
A 1.2-Mb custom SureSelect capture bait library (Agilent
Technologies, Santa Clara, CA, United States) was designed to
target 92 genes (listed in Supplementary Table 1), selected to
be the most frequently mutated genes in CUPs, as reported in
MSK Impact study CUP cohort (Zehir et al., 2017), including
druggable or potentially actionable alterations. The panel was
designed using Agilent SureDesign web application (v. 7.0,
Agilent Technologies)1 to cover coding exons and UTRs, with 25
flanking bases from 3′ and 5′ ends. This panel comprehends up
to 51,466 probes included in five probe groups, with 2 × tiling
density, balanced boosting, and 86% of probes with the most
stringent masking. Libraries were prepared using the custom gene
panel following SureSelectXT HS/SureSelectXT Low Input Target
Enrichment with Pre-Capture Pooling protocol (G9702-90005,
v. A0, June 2019, Agilent Technologies). An input of 50 ng of
gDNA (normal and tumor) underwent enzymatic fragmentation
according to SureSelect Enzymatic Fragmentation protocol
(G9702-90050, Revision B0, January 2020, Agilent Technologies).
Libraries from ccfDNAs of Pt #71 (A, C) and Pt#95 were prepared
starting from 25 ng of DNA bypassing the fragmentation step,
as described in a published application note (Barber et al.,
2017). Libraries were sequenced on NextSeq 500 (Illumina)
platform using High Output 2 × 75-bp flow cells. Variant calling
and paired analyses (tumor vs. normal) were performed using
SureCall software (v. 4.2), applying a filter for all samples at
5%, and at 1% for ccfDNAs. Somatic alterations were filtered
to only keep exonic non-synonymous single-nucleotide variants
(SNVs), insertions, deletions, multiple nucleotide variants, and
long deletions not detected in the normal sample.
Alterations with population allele frequency (Genome
Aggregation Database, GnomAD; Karczewski et al., 2020) higher
than 0.5% in Non-Finnish European (NFE) population were also
filtered out. All variants reported had a coverage higher than
100. Target sequencing data (92-gene custom panel) were used
to assess copy number variants using panelcn.MOPS pipeline
(Povysil et al., 2017). Variants triage and clinical classification was
obtained with Alissa Interpret software (Agilent Technologies).
Variants were also annotated using ANNOVAR (Wang et al.,
2010). Bioinformatic pathogenicity prediction, reported in
1https://earray.chem.agilent.com/suredesign/
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Tables 1, 2, of the identified variants was performed consulting
the prediction score/outcome of SIFT (Sort Intolerated From
Tolerated; Vaser et al., 2016), Polyphen2 HVAR (Polymorphism
Phenotyping v2; Adzhubei et al., 2010), LRT (Likelihood Ratio
Test; Chun and Fay, 2009), Mutation Taster (Schwarz et al., 2014),
Mutation Assessor (Reva et al., 2011), FATHMM (Functional
Analysis Through Hidden Markov Model; Shihab et al., 2013),
CADD (Combined Annotation Dependent Depletion; Kircher
et al., 2014), and VEST (Variant Effect Scoring Tool; Douville
et al., 2016). Genes with evidence for actionability and the
FDA-approved drugs reported in Tables 1, 2 were obtained
consulting OncoKB (Chakravarty et al., 2017).
Single-cell genomic DNA from DEPArray NxT sorted cells,
amplified using the Ampli1TM WGA Kit, was processed
to obtain Illumina-compatible libraries using the Ampli1TM
OncoSeek Panel and the Ampli1TM LowPass kits. Conversely,
tumor gDNA was directly processed with DEPArrayTM LibPrep
and DEPArrayTM OncoSeek Panel kits. After sequencing
on MiSeq platforms, raw data were analyzed using assay-
specific applications on the MSBiosuite platform (Menarini
Silicon Biosystems).
FFPE tumor tissue of Pt#71 was eligible for genetic
testing using FoundationOne CDx (F1CDx) assay. F1CDx
is performed exclusively as a laboratory service using DNA
extracted from FFPE tumor samples. A library was prepared
with a hybrid capture−based target enrichment approach
and whole−genome shotgun library construction to detect
substitutions, indels, copy number alterations, and selected
rearrangements in a total of 324 genes. Sequencing was
performed using the Illumina HiSeq 4000 platform, obtaining
a >500 × median coverage. F1CDx specimens were also
simultaneously profiled for tumor mutation burden (TMB)
and microsatellite instability (MSI) status (further technical
information is available at https://www.foundationmedicine.
com/genomic-testing/foundation-one-cdx).
Droplet Digital PCR Validation
Droplet Digital PCR technology (Bio-Rad, Hercules, CA,
United States) along with Mutational and Copy Number
Determination assays (Bio-Rad) were used to validate specific
alterations in both genomic and ccfDNAs. A Copy Number
Variation assay was used to assess the amplification of FGFR2
gene (dHsaCB2500320, Bio-Rad) using RPP30 as reference
gene (dHsaCP2500350, Bio-Rad). A digestion with HaeIII
restriction enzyme was performed during ddPCR, according
to the manufacturer’s instruction. Mutational assay for wild-
type and mutated ARID1A (p.R1276∗) was performed with a
custom IDT assay (02516372). For this assay, DNA digestion
with HindIII restriction enzyme was performed only for gDNA.
Probe-based Droplet Digital PCR experiment was performed
according to the manufacturer’s instruction and thermal cycling
conditions were 95◦C for 10 min, 94◦C for 30 s and 58◦C for
1 min for 40 cycles, 98◦C for 10 min, and an infinite hold
at 4◦C (ramping rate reduced to 2%). Droplet selection was
performed individually for each well using QuantaSoft software





A 49-year-old woman with a history of primary biliary
cholangitis (PBC) was admitted at Bologna University Hospital
in June 2018 due to enlarged left cervical lymph nodes
associated with severe asthenia, pruritus, and fever. A contrast-
enhanced computed tomography (CT) scan showed multiple
pathologic abdominal (epigastrium, mesogastrium, stomach
curvature, hepatic hilum, pancreatic, and retroperitoneal regions)
and left supraclavicular lymph nodes, confirmed also by a
F-Fluorodeoxyglucose positron emission tomography/computed
tomography (18-F-FDG PET/CT) scan. The patient underwent
abdominal surgery leading to the excision of two lymph nodes.
Pathological examination confirmed the presence of nodal
metastasis from adenocarcinoma.
Immunohistochemistry staining reported positivity
for keratin 7, keratin 20, and CDX2, and negativity for
neuroendocrine markers (chromogranin, synaptophysin, and
CD56). Therefore, the conclusive pathological diagnosis was
suggestive of lymph node metastasis from adenocarcinoma
of the gastrointestinal tract. Esophagogastroduodenoscopy
(EGDS) and pancoloscopy (PC) failed to identify any neoplastic
lesion. In addition, molecular analyses for the determination of
MSI, HER2, ALK, and PD-L1 status (by IHC); KRAS, NRAS,
BRAF mutational status and MGMT methylation status (by
pyrosequencing); and ROS1 and MET (by FISH) were all
negative. Among the serum oncomarkers, the positive ones were
Ca19.9 (291 U/ml, n.v < 40 U/ml), Ca125 (130.9 U/ml, n.v < 35
U/ml), and NSE (34 µg/L, n.v < 12 µg/L).
Taking into account the history of PBC and its association
with a higher risk of cholangiocarcinoma, a magnetic resonance
cholangiopancreatography (MRCP) and MRI with contrast was
performed and ruled out the presence of any tumor lesion.
Then, the patient was treated with FOLFOX-4 as first-line
treatment every 2 weeks up to 11 courses, obtaining a partial
response. A maintenance treatment based on De Gramont
regimen (FULCV) was continued for four courses followed by
a worsening of patient’s clinical condition and the appearance
of pleural and abdominal effusions. Blood was collected for
CTC analysis with CELLSEARCH and DEPArray at November
2018. Treatment with Pazopanib, a novel multi-kinase inhibitor
(VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit, and
c-Fms/CSF1R), was proposed due to the presence of FGFR2
amplification (F1CDx testing). However, death occurred in June
2019 due to progressive disease and hepato-renal syndrome.
Pt#95
A 63-year-old woman was admitted at Bologna University
Hospital in February 2019 due to an edema of the upper limb.
Echo-Doppler scanning revealed thrombosis in basilica, axillary,
subclavian, internal jugular, and external jugular veins. The
patient experienced weight loss, asthenia, nausea, and cough.
A contrast-enhanced total body CT showed the presence of
supra- and infradiaphragmatic enlarged lymph nodes associated

















































































































































































APC chr5:112840254 4607insA p.T1556fs*3 9.8% 22.6% 29.9% ND 90.2%-99.2% 14.0% – – – – – – – – –
ARID1A chr1:26773456 c.C3826T p.R1276X 8.9% 28.5% 22.8% 7.3% NI NI – – – DC – – HF – –
ERBB3 chr12:56085144 c.C384A p.S128R 9.8% 20.7% 20.4% 8.5% NI NI – PS DT DC NFL TL BG HF –
NTRK1 chr1:156881475 C2206T p.Q736X 8.3% 26.0% 22.3% 7.6% NI NI DT – DT DC – – HF – –
KEAP1 chr19:10499630 c.G404A p.R135H 9.0% 22.6% 19.5% 7.0% NI NI TL PD DT DC NFL TL HF HF –
PALB2 chr16:23629735 C2419T p.P807S 9.0% 19.1% 16.6% 6.0% NI NI TL BG NL PM NFN TL BG BG Level 1/Olaparib*
KMT2C chr7:152265209 c.C1013T p.S338L ND 5.5% 4.3% NI NI NI TL PD U DC NFL DG BG BG –
KMT2C chr7:152247975 c.C2459T p.T820I ND 1.1% 1.1% NI NI NI DT PS DT DC NFL DG HF HF –
PTPRD chr9:8404618 c.T2908G p.L970V ND 5.1% 3.5% NI NI NI – PD DT DC FCM TL BG HF –
TP53 chr9:8404618 c.T316C p.C106R ND 2.1% ND ND ND ND DT PD DT DC FCM DG HF HF Levels 1–3/no drug
TP53 chr17:7674251 c.G315C p.M105I ND 1.8% ND ND ND ND DT PD DT DC FCM DG HF HF Levels 1–3/no drug
TP53 chr17:7674252 c.A355G p.I119V ND 1.7% ND ND ND ND DT PD DT DC FCM DG HF HF Levels 1–3/no drug
TP53 chr17:7674212 c.C9G p.C3W ND 1.2% ND ND ND ND DT PD DT DC FCM DG BG HF Levels 1–3/no drug
ALK chr2:29328463 c.A1301G p.K434R ND ND 7.0% ND OTR OTR – BG U DC NFN TL HF BG Level 1/Lorlatinib,
Brigatinib*
EPHA5 chr4:65420551 c.A1417C p.T473P ND ND 8.3% NI NI NI TL PS NL DC NFL TL BG HF –
FAT1 chr4:186707744 c.A2084C p.N695T ND ND 2.6% NI NI NI TL BG NL PM NFN TL BG BG –
MGA chr15:41736268 c.T4004C p.L1335P ND ND 1.6% NI NI NI DT PD NL DC NFN TL BG HF –
KMT2C chr7:152248206 c.C2228T p.P743L ND ND 1.6% NI NI NI TL BG NL PM NFN DG BG BG –
KMT2C chr7:152235897 c.C2689T p.R897X ND ND 1.4% NI NI NI – – – DC – – HF – –
PTPRD chr9:8389280 c.A3117C p.Q1039H ND ND 6.8% ND NI NI – PD DT DC FCM DG BG HF –
ABL1 chr9:133760790 c.C3113T p. A1038V NI NI NI 52.8% OTR OTR – BG – – NFN – HF – –
GRM3 chr7:86415916 c.C808T p.R270C NI NI NI 7.0% NI NI – PS – – FCM – HF – –
MAP3K1 chr5:56177843 c.C2816G p.S939C NI NI NI 49.6% NI NI – BG – – – – HF – –
MSH3 chr5:80149992 c.A2857T p.M953L NI NI NI 46.1% NI NI – PD – – FCM – HF – –
MSH6 chr2:48028273 c.G3151A p.V1051I NI NI NI 50.0% OTR OTR – BG – – NFL – BG – –
PTPRO chr12:15475691 c.G31T p.A11S NI NI NI 52.2% NI NI – BG – – NFN – BG – –
NI, not included; ND, not detected; OTR, out of target region; TL, tolerated; DT, deleterious; BG, benign; PD, Probably Damaging; PS, Possibly damaging; U, Unknown, NL, normal; DC, Disease causing; PM,
























































































































































































ARID1A chr1:26774679 c.4454_4457delTACA p.I1485Rfs*19 32.6% 25% NI - - - - - - - - -
ARID1A chr1:26774687 c.C4460T p.A1487V 33.2% 27% NI TL BG DT DC NFN TL BG HF -
SPEN chr1:15937527 c.G10391C p.G3464A 31.0% 24% NI TL BG - DC NFL TL BG BG -
PIK3CG chr7:106872869 c.G2218A p.E740K 22.0% 8% NI TL BG NL DC NFL TL BG BG -
FGFR2 chr10:121515254 c.G814A p.G272R 19.0% NC OTR DT PD DT DC FCM DG HF HF Level 4/Debio1347,
AZD4547, BGJ398,
Erdafitinib
KMT2D chr12:49031574 c.G13131A p.W4377X 17.0% FLQ NI DT – NL DC† – – HF – Level 3/no drug
FAT1 chr4:186621042 c.A5544C p.Q1848H 13.1% NC NI TL PD DT DC NFL TL BG HF –
KMT2C chr7:152265180 c.G1042A p.D348N 9.8% FLQ NI TL PD U DC NFL DG BG BG –
KMT2C chr7:152248140 c.A2294G p.E765G 7.8% ND NI TL BG DT DC NFL DG BG BG –
KMT2C chr7:152235876 c.C2710T p.R904X 7.5% FLQ NI TL – NL DC – – HF – –
KMT2C chr7:152235929 c.G2657A p.R886H 6.8% ND NI DT PS DT DC FCM DG HF BG –
KMT2C chr7:152235861 c.A2725G p.R909G 6.6% ND NI TL PD DT DC FCM DG BG HF –
KMT2C chr7:152248143 c.C2291T p.S764F 4.9% FLQ NI DT BG NL DC NFL DG BG BG –
KMT2C chr7:152265209 c.C1013T p.S338L 4.9% ND NI TL PD U DC NFL DG BG BG –
KMT2C chr7:152273774 c.G943A p.G315S 4.9% NC NI DT PD DT DC FCM TL HF HF –
KMT2C chr7:152247966 c.T2468C p.I823T 2.3% NC NI TL PD DT DC NFL DG BG HF –
MGA chr15:41767261 c.C8552T p.P2851L NC 5.20% NI TL PS NL DC NFN DG BG BG –
KMT2C chr7:152163206 c.C10371A p.D3457E NC 6.30% NI TL BG NL DC NFL DG BG BG –
PTPRD chr9:8521304 c.G904A p.E302K NC 5.00% NI – PD DT DC FCM TL HF HF –
ASXL2 chr2:25743628 c.G1929T p.Q643H NC 5.10% NI DT PD NL DC FCM TL BG BG –
NI, not included; NC, not covered region; FLQ, filtered for low quality; ND, not detected; OTR, out of target region; TL, tolerated; DT, deleterious; BG, benign; PD, Probably Damaging; PS, Possibly damaging; U,
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with edema and diffuse suffusion of mesenteric and perivisceral
tissues suggestive of peritoneal carcinosis, confirmed also by a
18F-FDG-PET/CT scan.
A CT-guided biopsy of a left paraortic lymph node led
to a pathological diagnosis of node metastasis from poorly
differentiated carcinoma with microglandular and signet-ring
architecture. At immunohistochemistry, cells presented a focal
positivity for K7 and CDX2 and negativity to K20 and
synaptophysin. The immunophenotypical findings suggested
to suspect a gastric primary tumor. Blood was collected for
CTC analysis with CELLSEARCH and DEPArray and Parsortix
at December 2019.
In May 2019, molecular analyses for the determination
of MSI and HER2 status (by IHC) were negative, as well
as KRAS, NRAS, BRAF, mutational status, and MGMT
methylation status (by pyrosequencing). The patient
underwent EGDS with ecoendoscopy, which found a
suspicious area in the ampulla of Vater. Histological
examination confirmed the presence of poorly differentiated
adenocarcinoma with mixed, micro-glandular pattern, and
signet-ring cells and a lymphangitic infiltration of the
mucosa of duodenal type. IHC analysis reported a strong
immunoreactivity to MUC1, MUC5AC, MUC6, and a
complete negativity to MUC2 in addition to the previously
identified K7+/K20−/CDX2+ profile, suggesting a likely
bilio-pancreatic origin.
Starting from May 2019, the patient was treated with
FOLFOX-4 regimen up to nine cycles, obtaining an initial partial
response. In October 2019, the patient was admitted at the
Emergency room of the Bologna University Hospital due to
dyspnea and bilateral pleural effusion. The patient underwent
pleural drainage and cytological examination, followed by video-
assisted thoracoscopy and pleurodesis. The cell block was tested
by IHC and the identified tumor cells were found to be
reactive for BEREP4, K7, and CDX2 and negative for TTF1
and calretinin. Molecular analysis on pleural-derived cytological
specimen was performed in the diagnostic setting. The analysis
reported a pathogenic alteration in FGFR2 gene (c.1150G > A,
p. Gly384Arg, AF:33.4%); no gene amplification or fusion
was detected. In December 2019, the patient started weekly
gemcitabine regimen as second-line treatment. After 2 weeks
from the first administration, the patient had uncontrolled ascitic
effusion. Abdominal CT with and without contrast showed
progressive disease due to evident radiological signs of peritoneal
carcinosis. The patient died in January 2020 due to further
progressive disease.
Identification and Characterization of
CTCs From CUP Patients Using
CELLSEARCH and DEPArray or Parsortix
Systems
CTCs from patients’ peripheral blood were isolated by combining
CELLSEARCH and the DEPArray system. For Pt#71, 66
(CK+/CD45−/DAPI+) cells (none of which was positive for PD-
L1) were captured with immunomagnetic beads. The isolated
cells were then loaded on DEPArray that retrieved n = 12 CTCs.
Three CTCs and one leukocyte as control were subjected to
single-cell whole-genome amplification and sequencing.
For Pt#95, CELLSEARCH captured 133 CTCs cells (defined
as above) from which DEPArray recovered 34 putative CTCs
(Figure 1 and Supplementary Figure 1). A total number of 32
CTCs and four leukocytes ware subjected to single-cell whole-
genome amplification, and 10 CTCs passed quality control
criteria for low-pass whole-genome analysis.
Pt#95 whole blood was also used to isolate CTCs with the
Parsortix system (ANGLE plc). Large cells were isolated with
a 6.5 µm Parsortix cassette. Some EpCAM-positive and CD45-
negative CTCs were captured in the cassette (Figure 2), together
with EpCAM-positive and CD45-positive cells of unknown
significance (Figure 2).
Mutational Analysis of CTCs, ctDNA, and
Tumor
Pt#71
F1CDx testing reported the amplification of FGFR2 (Copy
Number, CN: 49) and CCNE1 (CN: 8) genes along with a somatic
variant in ARID1A gene (p.R1276∗) with an allele frequency
(AF) of 7.3%. Moreover, F1CDx reported an intermediate tumor
mutational burden (13 mutations/Mb). Single-cell genome-
wide characterization of CTCs (Ampli1 LowPass, Menarini
Silicon Biosystems) allowed sub-chromosomal losses detection,
including a LOH region comprising the APC gene, and pattern of
extensive gains, including FGFR2 and CCNE1 genes (Figure 3).
The same alterations were confirmed on bulk tumor
DNA. Moreover, targeted sequencing (Ampli1 OncoSeek panel,
Menarini Silicon Biosystems) was able to detect the presence
of FGFR2 amplification in 3/3 CTCs and the inactivating
homozygous somatic variant in APC gene (p.T1556Nfs∗3, AF:
90.2–99.2%). The APC somatic variant, which was missed by
F1CDx, was detected (Figure 3) in two out of three analyzed
CTCs, while the third CTC shows no coverage in the APC region
(L5589, grayed out), in agreement with the deletion detected by
the LowPass copy number profile in this cell, and a single-WBC
control from the same sample (L5601) was wild type, as expected.
The tumor gDNA target sequencing (DEPArray OncoSeek panel,
Menarini Silicon Biosystems) confirmed the FGFR2 amplification
and reported the same frameshift variant in APC, even though
with a lower allele frequency (p.T1556Nfs∗3, AF: 14%), likely due
to contamination by normal cells. The single-copy homozygous
variant in APC found in CTCs is coherent with a ∼15% variant
frequency in the presence of 70% of normal cells in FFPE. Indeed,
when setting the contamination parameter to 70% in the FFPE
low-pass analysis, the bioinformatic pipeline was able to call,
out of the increased noise, some CNA regions similar to those
detected in CTCs, which were otherwise undetectable without the
correction factor (Supplementary Figure 2).
The SureSelect 92-gene custom panel detected the APC
insertion in bulk tumor DNA (AF:9.8%) and also in circulating
cfDNAs analyzed at two different time points (ccfDNA at
diagnosis, AF: 22.6% and ccfDNA at the progression of the
disease, AF:29.9%). The tool panelcn.MOPS (Povysil et al.,
2017) used to analyze target sequencing data confirmed the
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FIGURE 1 | DEPArray NxT analysis. Scatter plot of the enriched blood sample of patient#95. On the X-axis, the mean intensity fluorescence of PE channel is
reported, corresponding to the intensity of CK IF staining. On the Y-axis, the mean intensity of CD45-APC is represented.
FGFR2 and CCNE1 gene amplification reporting a copy number
alteration higher than four in both genes; however, no APC
loss was detected. Moreover, we confirmed the mutation in
ARID1A gene (p.R1276∗), ERBB3 (p.S128R), KEAP1 (p.R135H),
PALB2 (p.P807S), and NTRK1 (p.Q736X), previously reported
by F1CDx, both in the tumor and in the ccfDNAs. All detected
variants and CNVs are listed in Tables 1, 3.
In Table 1, we reported other mutations detected by F1CDx
in genes not included in the custom panel and some variants
detected in ccfDNAs not observed in the tumor. Of note, we
observed mutations in ALK (p.K434R, AF:7%), EPHA5 (p.T473P,
AF: 8.3%), PTPRD (p.Q1039H, AF:6.8%), and other alterations at
lower frequency.
Droplet Digital PCR technology validated the ARID1A
mutation (Figure 4A and Supplementary Figure 3A) and the
FGFR2 amplification (Figure 4B and Supplementary Figure 3B)
in bulk tumor DNA and in longitudinally collected ccfDNAs
at three different time points of disease evolution. Of note, the
frequency of ARID1A mutation decreases at time point B, during
FOLFOX-4 treatment, then it increases during the progression
of the disease, while the FGFR2 amplification has a decreasing
trend in terms of copy number value during disease progression.
The Variant Allele Frequency reported by target sequencing at
two time points was found to be consistent with the Fractional
Abundance (FA% = mutated copies/mutated copies + wild-type
copies) measured by ddPCR.
Pt#95
Single-cell whole-genome characterization of 10 CTCs detected
a recurrent amplification signal in the regions of ASPM and
SEPT9 genes and a deletion including FANCC gene in all
analyzed CTCs (Supplementary Figure 4), as shown in the
CNV profile clustering in Figure 5. CTCs and bulk tumor
DNA-targeted sequencing (Ampli1 OncoSeek Panel, Menarini
Silicon Biosystems) reported no somatic mutation in the regions
covered by the panel.
Target sequencing performed on ccfDNA and tumor FFPE
tissue with the 92-gene custom panel identified 16 non-
synonymous, somatic genetic alterations not detected in the
normal cells in the ccfDNA and 8 in the tumor DNA (Table 2),
including ARID1A deletion (I1485Rfs∗19, AF: 32.6%) and
mutation (p. A1487V, AF: 33.2%) and a mutation in FGFR2 gene
(p.G272R, AF:19%). Of note, mutational analysis performed in
the diagnostic setting (obtained with Oncomine Comprehensive
Assay by Thermo Fisher Scientific) reported the same mutation
in FGFR2 gene; no amplifications or deletions were detected with
Agilent custom panel, but regions including ASPM, SEPT9, and
FANCC genes were not captured.
DISCUSSION
The identification of driver and actionable genetic
alterations is crucial to broaden the treatment choices of
cancer patients. This is particularly relevant for patients
with CUP, who have reduced access to targeted and
immunotherapies. One main reason resides in treatment
protocols being designed in a tumor-gnostic way. Furthermore,
CUPs are characterized by scarce availability of tumor
material for genetic testing, due to the extensive use of
tissue slices in immune-phenotypic testing required for
diagnostic procedures.
In this pilot study, we took advantage of liquid biopsy
approaches to genetically characterize CUP tumors using both
CTCs and DNA as a source of tumor DNA, with the aim to
identify druggable genetic alterations.
The isolation and counting of CTCs is becoming an important
tool to evaluate aggressiveness and prognosis of different
solid tumors. The CELLSEARCH system (Menarini Silicon
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FIGURE 2 | Staining of cells isolated with Parsortix from patient #95. Cells
were forced to pass through a 6.5-µm cassette in the Parsortix system and
then stained with different antibodies. Nuclei stained with DAPI (blue), CD45
(red), and EpCAM (green). From top to bottom: double-positive cells (CD45+,
EpCAM+) of unknown significance, three exemplary CTCs (CD45-, EpCAM+),
one exemplary leucocyte (CD45+, EpCAM-) Scale bar, 50 µm
(double-positive cells) and 25 µm (CTCs and leucocyte).
Biosystems) is to date the only platform cleared by the FDA for
detecting and enumerating CTCs in metastatic breast, prostate,
and colorectal cancer patients, while other technologies are at
preclinical and clinical stages of development. CTC count as
measured by CELLSEARCH System proved to have prognostic
value in different metastatic solid tumors, including breast
(Cristofanilli et al., 2004), colorectal (Cohen et al., 2008), and
gastric cancers (Matsusaka et al., 2010). In addition, the detection
of one or more CTCs using this system was found to predict early
recurrence and a worse prognosis in chemo naïve patients with
non-metastatic breast cancer (Lucci et al., 2012). A considerable
number of CTCs were detected in the two CUP patients enrolled
in our study, and they were successfully enriched and enumerated
by CELLSEARCH and isolated with DEPArray for downstream
molecular analysis (Ampli1 kit).
Recently, CTC isolation methods based on label-free systems
were also developed. In one patient, we used the Parsortix
system (ANGLE plc) for the size-based enrichment of CTCs
from peripheral blood of CUP patients. This approach ensured
a size-based selection of CTCs without the need of specific
markers, which is a potential issue when isolating these cells from
CUP patients. Some CTCs enriched with the Parsortix system
proved to be positive for EpCAM marker, therefore confirming
their epithelial origin, although no genetic confirmation could
be produced. We also detected cells that co-express hemato-
epithelial markers, as previously reported for a subpopulation of
epithelial ovarian cancer tumor cells (Akhter et al., 2018). In this
paper, the authors proposed a cell–cell fusion theory to explain
the origin of these peculiar cell population. Indeed, EpCAM+
and CD45+ cells show more invasive mesenchymal properties
and overexpress genes related to drug resistance, anti-apoptosis,
and stemness. The detection of cells with these characteristics
in circulation could be associated with CUP highly invasive
phenotype and deserves further investigations.
CTCs and ccfDNA were used for CUP genetic testing. Our
results from two longitudinally monitored patients suggested
that CTCs and ctDNA can be isolated from the blood of CUP
patients and are suitable for genetic characterization. FFPE tumor
tissue was used to validate the liquid biopsy results. In addition,
we analyzed and compared different targeted sequencing
approaches applied to tumor FFPE tissue, CTCs, and ccfDNA:
FoundationOne CDx (Roche Foundation Medicine), OncoSeek
Panels (Ampli1 and DEPArray OncoSeek Panels, Menarini
Silicon Biosystems), and an in-house developed, Agilent
SureSelect panel, focusing on 92 genes frequently mutated in
CUPs and metastatic solid tumors. The comprehensive genomic
analysis was highly overlapping among the different approaches,
when the region was covered by all panels. Clearly, these
three different technologies cover a different number of genes
and hot spot regions, which explains the differential detection
of some variants.
Interestingly, both CUP patients presented actionable FGFR2
aberrations. Specifically, a ∼80-fold copy number amplification
(Pt#71) and a gene mutation (Pt#95), both at the tumor
and CTC/ctDNA level, suggest a potential implication of this
pathway in tumor progression and aggressiveness (Dienstmann
et al., 2014). FGFR2 is a member of the fibroblast growth
factor receptor family, whose signaling pathway activates
downstream effectors that play a crucial role in cell proliferation,
survival, and migration (Turner and Grose, 2010). FGFR2
rearrangements have been detected in 10–15% of intrahepatic
cholangiocarcinomas (Arai et al., 2014; Silverman et al., 2019),
amplifications in up to 15% of gastric cancers (Deng et al., 2012;
Seo et al., 2017) and point mutations in about 10% of endometrial
cancers (Byron et al., 2012); moreover, FGFR2 amplification
has also a prognostic significance in gastric cancers (Chang
et al., 2014; Seo et al., 2017). Of note, in longitudinal ccfDNAs
from Pt#71, we observed a progressive reduction of FGFR2 CN
during treatments, which mirrors the initial partial response.
Taking into account the chemo-naïve status of the two patients
and the unavailability of clinical trials testing multi-kinase or
FGFR2 inhibitors in CUP patients, the patients were treated
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FIGURE 3 | Whole-genome copy number profiles and mutation analysis of CTCs and FFPE gDNA from patient #71. (A) Detection of a homozygous somatic variant
(absent in a single WBC), in two out of three CTCs in APC gene (APC:p.T1556Nfs*3), a region also subjected to LOH, and the detection of the same variant in the
FFPE tissue at lower frequency, due to the possible contamination by normal cells. (B) Representative copy number profile of one CTC. Amplification signal was
detected for FGFR2 and CCNE1 genes, indicated with red arrows. The LOH region in chromosome 5, comprising the APC gene, is indicated with a blue arrow.
(C) LowPass profile of L5589 CTC showing the complete deletion of APC genomic region, in agreement with the lack of coverage in targeted sequencing (grayed
out in A). (D) Copy number aberration (CNA) distribution showing FGFR2 amplification in all three CTCs (D) and FFPE biopsy (E).
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Gene Alteration Tumor FFPE (CN) ccfDNAs (CN) Tumor FFPE (CN) CTC (CN) Tumor FFPE (CN)
FGFR2 Amplification >4 >4 49 > 80 82
CCNE1 Amplification >4 >4 8 6 5
APC Loss/deletion Not detected Not detected Not detected Detected Detected
with platinum salts and fluoropyrimidines, as suggested by the
current guidelines.
Pt#71 also presented an amplification in CCNE1 (Cyclin E1)
gene, which is known to be associated with poor prognosis in
ovarian and triple-negative breast cancer, probably involved in
the emergence of resistance to chemotherapy (Nakayama et al.,
2010; Huang et al., 2020).
Another common genetic feature of the two tested CUP
tumors was the presence of alterations in ARID1A gene, which
is a tumor suppressor gene encoding the DNA-binding subunit
FIGURE 4 | Kinetics of mutated fractional abundance and CNV in longitudinal
ccfDNAs measured by Droplet Digital PCR. The graph in (A) illustrates
ARID1A mutated fractional abundance (p.R1276X) during patient’s follow-up.
This value decreases during treatment and later rises at the worsening of
patient’s conditions; on the contrary, when monitoring FGFR2 amplification at
the same time points, as reported in (B), a decreasing trend was detected
from the diagnosis to disease progression.
of the chromatin remodeler complex SWI/SNF (Trizzino et al.,
2018). Despite not being druggable, this gene is the most
frequently mutated chromatin regulator across all human cancers
(Kadoch et al., 2013) and its loss impairs RNA polymerase II
(RNAPII) pausing. Compromised RNAPII pausing results in
transcriptional dysregulation of active genes, such as TP53 and
ESR1, which could explain the oncogenic effects of ARID1A
loss (Trizzino et al., 2018). The recurrence of these mutation
in both reported cases open an interesting prospective on the
role of ARID1A in regulating the aggressiveness of CUPs.
Of note, when longitudinally evaluated in ccfDNAs of Pt#71,
the Fractional Abundance of ARID1A mutation (p.R1276∗)
decreased during treatment and then increases at disease
progression, suggesting its potential involvement in disease
worsening. Moreover, we noticed that in ccfDNAs at diagnosis
and disease progression, in which the Fractional Abundance
of ARID1Amut was high, there was also the emergence of
novel mutations in TP53, ALK, EPHA5, FAT1, and MGA
genes, not detected in the tumor biopsy. In vitro experiments
demonstrated that ARID1A deficiency leads to DNA replication
stress (Tsai et al., 2020) and impaired checkpoint activation and
repair of DNA double-strand breaks (DSBs), which sensitizes
to DSB-inducing treatments (Shen et al., 2015). Moreover,
ARID1A normally recruits MSH2 to chromatin during DNA
replication and promotes mismatch repair (MMR); however,
its deficiency is associated with the impairment of MMR and
thus an increase in mutagenesis and mutational load (Shen
et al., 2018). As a consequence, ARID1A deficiency has been
investigated as a biomarker of response to anti-PD-1/PD-L1
immunotherapy treatment (Okamura et al., 2020); alterations
in this gene were found to be associated with a longer
PFS in patients treated with anti-PD-1/PD-L1 immunotherapy
(regardless of microsatellite and tumor mutational burden
status). It has been demonstrated that 15% of CUP patients
harbor alterations in ARID1A gene (MSK impact study; Zehir
et al., 2017). Therefore, immune checkpoint inhibitors could
be considered as a therapeutic option for ARID1A mutated
CUP cases. In the two CUP cases investigated in this study,
ARID1A-dependent accumulation of genetic alterations could
explain the number of novel mutations that were longitudinally
detected in the ccfDNA.
However, another explanation could be that the
mutation load was boosted by the mutagenic activity
of oxaliplatin (L-OHP), a DNA-alkylating-like agent,
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FIGURE 5 | Clustering analysis of 10 CTCs based on whole-genome copy number profile. The heatmap represents the relative copy number profiles of 10 different
CTCs isolated through CELLSEARCH R© and DEPArrayTM technologies. Segments of gains or deletions are color-coded according their relative log2 copy number
ratios.
which is included in FOLFOX-4 chemotherapy
combination along with Leucovorin and 5-fluorouracil
(5-FU) (Silva et al., 2005; Kawamoto et al., 2012).
This chemotherapy regimen is commonly used to
manage metastatic colorectal cancer (Benson et al.,
2014), but also administered to CUP patients with
K20+/K7−/CDX2+ IHC signature.
Overall, our analysis constitutes the proof of concept
needed to assess the relevance of liquid biopsy genetic testing
in metastatic cancer of unknown origin and underlies the
importance of using dedicated NGS panels to identify actionable
genetic alterations.
Altogether, our results support the use of liquid biopsy,
either using CTCs or ccfDNA, in the genetic characterization
of CUPs and identification of driver mutations, with the
advantage of a minimally invasive approach and potential
longitudinal monitoring. This is a proof-of-concept study
on a small number of patients, but given the rarity of the
disease and the great need for effective therapies, we believe
we provided valuable novel data. We can also conclude
that a timely genetic testing and the use of broad or
CUP-dedicated NGS panels, covering the most frequently
mutated genes, are of the outmost importance to offer
these patients novel therapeutic options and potentially
improve their survival.
DATA AVAILABILITY STATEMENT
The datasets presented in this article are not readily available
because patients have consented to the use of their individual
genetic data for biomedical research, but not for unlimited public
Frontiers in Cell and Developmental Biology | www.frontiersin.org 12 June 2021 | Volume 9 | Article 666156
fcell-09-666156 June 4, 2021 Time: 17:55 # 13
Laprovitera et al. Liquid Biopsy in CUP
data release. Requests to access the datasets should be directed to
corresponding author.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by the Ethics Committee Center Emilia-
Romagna Region – Italy (protocol 130/2016/U/Tess). The
patients/participants provided their written informed consent to
participate in this study.
AUTHOR CONTRIBUTIONS
NL, IS, EP, MR, MG, PT, and SV carried out the experiments and
data analysis. MF wrote the manuscript with support from NL,
IS, FG, AA, FF, NM, MP, and SS. AD’E and AA helped supervise
the project. MF conceived the original idea and supervised the
project. All authors contributed to the article and approved the
submitted version.
FUNDING
The research leading to these results has received funding
from AIRC under IG 2016–ID. 18464 project–P.I. Ferracin
Manuela and CaMMPPO study sponsored by Menarini Silicon
Biosystems S.p.A. NL was supported by eDIMES Lab funds from
Bologna University. The authors would like to thank Fondazione
del Monte di Bologna e Ravenna for the financial support.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fcell.2021.
666156/full#supplementary-material
Supplementary Figure 1 | DEPArray NxT representative CTC images from
patient #95. Cell gallery acquired by DEPArray, showing single fluorescent
channels and overlays, and bright field (BF) images where the DEPArray
electrodes (pitch 20µm) are visible.
Supplementary Figure 2 | Patient #71: Low-Pass Whole Genome CNA profiles.
(A) FFPE without compensation: the signal produced by normal cells impact the
copy-number alterations (CNA) call. (B) Pure single-CTC: clear CNA calls with
digital copy-number values (e.g., Chr 8q n = 4). (C) FFPE analysis set at 70%
normal DNA contamination: signal is amplified and, among increased noise, some
true positive CNA detected also in CTCs are called (green arrows) along with
putative false-positives (orange arrows).
Supplementary Figure 3 | Mutational assay and copy number determination
assay by Droplet Digital PCR. The graph reports ddPCR outputs of ARID1A
mutated fractional abundance (p.R1276X) (A) and in FGFR2 amplification (B)
during patient’s follow-up at three different time points.
Supplementary Figure 4 | Patient #95 single-CTCs images and CNA profiles.
Cell gallery acquired by DEPArray, showing single fluorescent channels and
overlays, and bright field (BF) images for 10 CTCs, paired with the
corresponding CNA profile.
Supplementary Table 1 | List of genes and regions included in
SureSelect custom panel.
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